OncoDNA Presentations & Investor Relations material

Based in Belgium, OncoDNA is a leader in personalised molecular analysis for cancer patients. OncoKDM, a software for data interpretation and reporting, is the latest addition to the four solutions that OncoDNA is offering on the market, namely OncoDEEP, OncoTRACE, OncoSTRAT&GO and our latest liquid biopsy solution OncoSELECT. These medical innovations assist medical doctors with treatment choice and/or provide better monitoring of tumor evolution in patients. Since OncoDEEP was officially launched in June 2014, OncoDNA has been developing his distribution network and it has already around 30 distributors covering over 60 countries. This means that patients from all over the world have access to our services. OncoDNA is involved in several big scientific projects such as the AURORA research program, which aims to understand metastatic breast cancer. The role of OncoDNA in the study is to perform analysis on the biological samples collected from over 1000 patients with metastatic breast cancer from over 80 hospitals across Europe. In April 2016, OncoDNA has officially launched OncoTRACE, which is the first test in the world which is really personalized. It uses a blood sample to monitor the progression of a patient's tumor and to rapidly assess treatment effectiveness. The purpose of this innovative, non-invasive test is to sequence circulating tumor DNA, in the blood. In September 2016, OncoDNA has announced the closing of a equity financing at EUR 7.7 million. The new shares were subscribed for by both the historical shareholders amongst IPG, Sambrinvest as well as a group of four new investors (AVH, SRIW, CPH, and Inventures). In October 2016, OncoDNA has signed an agreement with SOLTI to Provide Tumor Molecular Profile Analysis to Breast Cancer Patients in AGATA Screening Program. This Program will use OncoDNA's platform called OncoKDM (Knowledge Drive Medicine) to answer the specific needs of AGATA, allowing the integration of three different types of DNA data, RNA and proteomic data. In May 2017, OncoDNA has officially launched OncoKDM. This SaaS (Software as a Service) application will allow the experts of OncoDNA to interpret the data generated by different cancer treatment facilities on a global scale. Oncologists from around the world are now able to receive a detailed and interactive report that contains essential information to help them select the right treatment to fight their patient's tumour. OncoKDM can thus provide daily support to oncologists and laboratory heads, since it can process a considerable volume of data, received in different formats, in record time. OncoDNA interprets the raw data remotely via a secure online platform!